The company’s agreement with the Israel Tax Authority, ITA, has no impact on Teva‘s 2024 financial outlook, which the Company reaffirms.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA:
- Corcept Therapeutics weakness a buying opportunity, says Canaccord
- Teva sues Corcept over alleged mifepristone market monopoly, Reuters says
- Teva call volume above normal and directionally bullish
- Teva price target raised to $21 from $20 at Barclays
- Teva presents first real-world data from IMPACT-TD Registry study